Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

21

Possibly Marketed Outside US

5

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Glucocorticoid receptor

21

Mineralocorticoid receptor

21

Prostaglandin G/H synthase 1

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

26

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1958

21

2019

5

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acne rosacea

21

Allergic conjunctivitis

21

Bacterial conjunctivitis

21

Corneal injury

21

Cyclitis

21

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

26

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

26

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Merck Sharp & Dohme

21

Hoechst

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

25

Mixture

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

26

CAS

25

PUBCHEM

25

EPA CompTox

23

SMS_ID

19

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

2

ALIMENTARY TRACT AND METABOLISM

1

CARDIOVASCULAR SYSTEM

1

DERMATOLOGICALS

1

RESPIRATORY SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANALGESICS

2

ANTI-ACNE PREPARATIONS

1

CORTICOSTEROIDS FOR SYSTEMIC USE

1

CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

1

NASAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANALGESICS AND ANTIPYRETICS

2

AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

1

ANTI-ACNE PREPARATIONS FOR TOPICAL USE

1

ANTIINFLAMMATORY AGENTS

1

ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Pyrazolones

2

Corticosteroids

1

Corticosteroids and antiinfectives in combination

1

Corticosteroids for local oral treatment

1

Corticosteroids, combinations for treatment of acne

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

24

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 26 results

First page disabled
Previous page disabled
1
Next page
Next page

DEXAMETHASONE

7S5I7G3JQL

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DIPYRONE

6429L0L52Y

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2019

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Prostaglandin G/H synthase 1

Conditions:

Dipyrone, also known as Metamizole (INN), is an ampyrone sulfonate analgesic, antispasmodic and antipyretic. It was withdrawn from US market in 1977 on the basis of reports of agranulocytosis. Depyrone is still used to treat severe and diffucult for ...

relieving pains of different origin; headache, tooth-ache, pains in the joints, muscles, following traumas and operations, gall and kidney colics, neurites, neuralgias, traumatic cerebrasthenia; inflammation of upper respiratory ways of microbial or virus origin; chorea; febrile states. Mechanism of action of dipyrone is complex. It is believed that dipyrone exerts its action by inhibiting COX-3, and activates opioid and cannabioid systems either itself, or by products of its metabolic degradation.

Dexamethasone 21-sulfate

VMN9Z37FQR

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DEXAMETHASONE SODIUM SUCCINATE

UZA9VMT64W

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DEXAMETHASONE SUCCINATE

9UY5TBO121

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DEXAMETHASONE 21-VALERATE

F2EHP3G50P

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DEXAMETHASONE SODIUM SULFATE

41B47ECP9F

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DEXAMETHASONE METASULFOBENZOATE

C67221CB9Q

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DEXAMETHASONE 21-METHANESULFONATE

O9S11FMA79

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

DEXAMETHASONE DIPROPIONATE

K3UKR54YXW

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Glucocorticoid receptor

Glucocorticoid receptor

Mineralocorticoid receptor

Conditions:

Herpes zoster keratitis

Allergic conjunctivitis

Superficial punctate keratitis

Bacterial conjunctivitis

Multiple myeloma

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune respo...

nse. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

Showing 1 - 10 of 26 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1